Odevixibat Outcomes in Patients With PFIC Versus an External Control Cohort (OvEC-PFIC)

NCT07497724 · tracked via the Priya Life Science France tracker

Sponsor

Ipsen

Phase

Observational

Started

2026-04-26

Last updated

2026-10-01

Condition(s) studied

PFIC - Progressive Familial Intrahepatic Cholestasis

Study summary

Progressive familial intrahepatic cholestasis (PFIC) is a rare inherited liver disease that causes a build-up of bile acids in the liver. This can lead to severe itching (pruritus), poor sleep, impaired growth, liver damage, and in some cases the need for surgery or liver transplantation.

The purpose of this non-interventional, retrospective study is to compare long-term health outcomes in patients with PFIC. The comparison is between patients who received odevixibat in two odevixibat clinical trials (Studies A4250-005 and A4250-008) and an aligned, balanced external control cohort of patients with PFIC from the Natural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) registry who were not treated with odevixibat (or other ileal bile acid transporter \[IBAT\] inhibitors). Outcomes such as liver transplantation, death, and surgical biliary diversion (SBD) will be examined to better understand how treatment with odevixibat compares to the natural course of PFIC. This study aims to provide a robust comparative evaluation of long-term clinical outcomes with odevixibat.

Eligibility

Sex

ALL

Min age

3 Months

Max age

100 Years

Healthy volunteers

Part A Eligibility: Comparisons to Evaluate the Effect of Odevixibat Versus SBD-naïve Odevixibat Cohort: * Patients treated with odevixibat in A4250-005 with at least one post-odevixibat assessment and who did not have prior LT or SBD. OR * Patients treated with placebo in A4250-005, first received odevixibat in Cohort 1 of A4250-008 with at least one post-odevixibat assessment, and meet the additional eligibility criteria OR * Patients treated with odevixibat in Cohort 2 of A4250-008 with at least one post-odevixibat assessment and who meet the additional eligibility criteria External Control Cohort: * A male or female patient in NAPPED registry not enrolled in A4250-005 or A4250-008. * The patient must be IBAT inhibitor-naïve (has not received prior treatment with odevixibat, maralixibat, or other IBAT inhibitors). * Patients must have clinical genetic confirmation of PFIC (any type), excluding known pathologic variations of the ABCB11 gene that predict complete absence of the BSEP protein. * The patient has at least one visit in NAPPED (the first of which becomes the Day 1 visit for this cohort) where they meet the eligibility criteria * Patients must be in the regions that participated in A4250-008. Part B Eligibility: Comparisons to Evaluate the Effect of Odevixibat Versus SBD Odevixibat Cohort * Same as Part A External Control Cohort: * A male or female patient in NAPPED registry with clinical diagnosis of PFIC (any type) and not enrolled in A4250-005 or A4250-008. * The patient must be IBAT inhibitor-naïve (has not received prior treatment with odevixibat, maralixibat, or other IBAT inhibitors). * Patient must have clinical genetic confirmation of PFIC (any type), excluding known pathologic variations of the ABCB11 gene that predict complete absence of the BSEP protein; * The patient underwent SBD (the date of surgery becomes the Day 1 visit for this cohort) but did not previously undergo a LT. * The patient meets the additional eligibility criteria. * Patients must be in the regions that participated in A4250-008.

Primary outcome measure(s)

Part A: Liver transplant-free survival (LTFS) — From the date of first odevixibat treatment or from the date of first registry entry into NAPPED group where OvEC cohort eligibility criteria were met, until the first occurrence of the defined event or last available follow-up (2017-2025)
Defined as time from Day 1 to the first occurrence of any of the following clinical events: Death (any cause); Liver Transplant (LT)
Part B: Liver transplant-free survival (LTFS) — From the date of first odevixibat treatment (Odevixibat Cohort) or from the from the date of SBD (External control cohort) until the first occurrence of the defined event or last available follow-up (2017-2025)
As defined for Part A

Trial sites (1)

Facility	City	Region	Status
Not applicable - retrospective secondary use of data	Paris	France

More Ipsen trials in France

A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours Active, not recruiting

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis Recruiting

A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows Active, not recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07497724 on ClinicalTrials.gov ↗ ← All trials in France